Please login to the form below
sarcoma
This page shows the latest sarcoma news and features for those working in and with pharma, biotech and healthcare.
Nektar’s opioid analgesic slammed with FDA panel rejection
This includes studies, either underway or planned, in small cell lung cancer, breast cancer, colorectal cancer, gastric cancer, triple-negative breast cancer, sarcoma, melanoma, renal cell carcinoma, bladder cancer and
Latest news
-
MD Anderson exec Stephen Hahn to be nominated FDA commissioner
He is also specialist in lung cancer and sarcoma, and climbed up the centre’s professional ladder since joining in 2015.
-
Bicycle Therapeutics looks to raise $86m with IPO
breast, lung, sarcoma, gastric, bladder, endometrial, ovarian and oesophageal cancers.
-
CHMP nod for Alexion, GSK drugs, revocation for Lartruvo
Authorisation revoked for Lartruvo. Friday’s ruling was also notable for the CHMP’s decision to revoke the marketing authorisation for Eli Lilly’s sarcoma treatment Lartruvo, after the drug failed
-
Lilly to withdraw Lartruvo, a first for accelerated approval failures
Existing patients can use access programme. Eli Lilly is to withdraw its soft tissue sarcoma treatment Lartruvo from the market after it failed a post-marketing efficacy study. ... Advanced soft tissue sarcoma is a rare and difficult-to-treat cancer.
-
Positive data unlocks more EIB funding for Nanobiotix
as well as an independent assessment of the clinical benefit/risk ratio for NBTXR3 in a phase 3 programme in soft tissue sarcoma (STS).
More from news
Approximately 5 fully matching, plus 47 partially matching documents found.
Latest Intelligence
-
Europe vs the US: New drug product approvals
Among the noteworthy approvals are Lartruvo (for the treatment of soft tissue sarcoma, approved in the EU and US), Rubraca (for the treatment of ovarian cancer, only approved in the US),
-
Case study: Treatment guidance
The Practical Guide was launched as part of a Takeda sponsored symposium at the British Sarcoma Group’s annual conference.
-
Pharma deals during February 2014
Also, this month Merck &Co has handed back the rights to Ariad Pharmaceutical's ridaforolimus, a mTOR inhibitor in a phase III trial for advanced sarcoma.
-
Interview: Harvey Berger and Timothy Clackson, Ariad
And that was absolutely correct.”. After selling off investigational sarcoma treatment ridaforolimus to Merck &Co following an aborted collaboration attempt, ponatinib emerged as the front-runner in the company's pipeline
More from intelligence
Approximately 0 fully matching, plus 4 partially matching documents found.
Latest from PMHub
-
5 creative tactics for your patient recruitment strategies
Videos such as this one from the Sarcoma UK Clinical Trials Hub explain how trials work, answer typical questions and present the benefits to possible participants.
-
World AIDS Day 2018: Fighting the stigma surrounding HIV
2. Characterised by very low levels of CD4+ T cells, and the presence of AIDS-related pathologies (such as tuberculosis and Kaposi’s sarcoma), the diagnosis of AIDS marks just how
More from PMHub
Approximately 0 fully matching, plus 2 partially matching documents found.
COVID-19 Updates and Daily News
Featured jobs
-
Healthcare Senior Account Manager
-
Competitive
- Sales Director, Healthcare communications agency, London/ SE UK
-
Six figure salary
-
Healthcare Lead Copywriter
-
Competitive
-
Healthcare Account Director
-
Competitive
- Account Manager Healthcare / Pharmaceutical Sector
-
Negotiable Salary
-
Medical Editor
-
Competitive
- PHE study finds people who have had COVID-19 can still transmit the virus
- Sinovac’s COVID-19 vaccine appears safe in older adults
- PHE study finds people who have had COVID-19 can still transmit the virus
- GSK’s PD-1 inhibitor dostarlimab shows updated promise in dMMR solid tumours
- New study identifies drugs that are safe to use in COVID-19 treatment
- AZ seeks EU approval for its Oxford University-partnered COVID-19 vaccine
- Onyx Health Celebrates Its 10th Anniversary with Five New Hires
- Merck’s appeal to restore hepatitis C patent verdict against Gilead fails
- Moderna cooperating with investigation into possible COVID-19 vaccine allergic reactions
- Trial combining British and Russian COVID-19 vaccines could begin in February
- New Oxford research institute established to tackle antimicrobial resistance
- EU proposes vaccine-sharing mechanism with low-income countries
PMHub
Life Healthcare Communications
Life is a creative communications agency offering multi-channel solutions for the healthcare industry. We use a storytelling approach to turn...
Latest intelligence
- Sourcing R&D innovation: why pharma companies need to evolve their business models
- Recent years have seen a significant shift in drug development to specialty areas...
- 2020 - a year to remember or forget?
- 2020 and the Covid pandemic brought immense challenges, and the need for change felt like it happened overnight. What have we learned and what does the future of agency working...
- The search for effective drug treatments for COVID-19
- PME talks to Julian Cole, Senior Director, Medical Affairs at Gilead Sciences...
Quick links
Infographics
